BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Phase 4
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00986778
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00983957
- Locations
- 🇺🇸
MDS Pharma Services (US), Inc, Tempe, Arizona, United States
🇺🇸Covance Clinical Research Unit, Inc., Austin, Texas, United States
🇨🇦Local Institution, St. Laurent, Quebec, Canada
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 238
- Registration Number
- NCT00982488
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸Ucla Department Of Medicine, Los Angeles, California, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00979316
- Locations
- 🇺🇸
Mds Pharma Services (Us), Inc, Tempe, Arizona, United States
Safety Study of BMS-816336 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DyslipidemiaDiabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: BMS-816336Drug: Placebo
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00979368
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00978731
Continue Entecavir Rollover From China
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT00975091
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT00971841
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00971945
- Locations
- 🇯🇵
Local Institution, Toshima-ku, Tokyo, Japan
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00971867
- Locations
- 🇯🇵
Local Institution, Tochigi, Japan
© Copyright 2025. All Rights Reserved by MedPath